Samarendra N Maiti

Title: **Samarendra N Maiti: A Pioneer in Antibacterial Innovations**

Introduction

Samarendra N Maiti, based in Edmonton, Canada, is a distinguished inventor renowned for his contributions to pharmaceutical innovations, particularly in the field of antibacterial agents. With a remarkable portfolio of 21 patents, his work has significantly advanced the development of effective treatments for bacterial infections.

Latest Patents

Among his latest patents are significant advancements in pharmaceutical compositions. One patent focuses on "Pharmaceutical compositions comprising LTV-17 and beta-lactamase inhibitors and their use as antibacterial agents." This innovation provides combinations of LTV-17, a lactivicin derivative, and β-lactamase inhibitors, enabling more effective treatments against bacterial infections. Another notable patent is for "Lactivicin compounds, their preparation and use as antibacterial agents." This patent details lactivicin compounds, their formulations, and their efficacy as antibiotics, whether utilized alone or alongside other antibiotic classes, for combating bacterial diseases.

Career Highlights

Throughout his career, Samarendra has been affiliated with various esteemed organizations, including Synphar Laboratories Inc. and Fedora Pharmaceuticals Inc. His work with these companies has propelled advancements in pharmaceutical sciences and helped bring innovative solutions to the market, particularly in combating antibiotic resistance.

Collaborations

Samarendra has collaborated with notable professionals in the field, including Ronald G Micetich and Jehangir Khan. These collaborations have facilitated knowledge exchange and fostered a creative environment ripe for innovation, leading to groundbreaking discoveries in antibacterial treatments.

Conclusion

Samarendra N Maiti stands out as a leading inventor in the pharmaceutical industry, particularly in the fight against bacterial infections. His extensive patent portfolio and collaborative efforts illustrate his commitment to advancing medical science and improving public health through innovative treatments. As research continues, his contributions remain vital to the future of effective antibacterial therapies.